Herombopag for low platelets from T-DM1 in breast cancer
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have breast cancer that was treated with anti-HER2 therapy before surgery and then with T-DM1 after surgery.
- You had low platelets (grade 2 or higher) from T-DM1 in your last treatment cycle, and your platelets have recovered to between 100 and 200 before the next dose.
- You are able to do daily activities with some help (ECOG score 0-2).
- You plan to receive at least two more cycles of T-DM1 at the same dose as your last cycle.
- You do not have other cancers in the last 3 years, blood disorders, recent blood clots, or severe bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called Herombopag can prevent low blood platelets, a common side effect of the breast cancer treatment T-DM1. If you are about to start T-DM1, this trial may help maintain healthy platelet levels.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This study tests a drug called hetrombopag to see if it can help prevent a drop in blood platelets (cells that help blood clot) caused by antibody-drug conjugate (ADC) cancer therapy. It may help patients who have already had low platelets from their treatment or are about to start an ADC regimen.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This trial studies a pill called herombopag to see if it can prevent low blood platelets caused by chemotherapy (and sometimes radiation) in people with cervical cancer. Low platelets increase the risk of bleeding, and this drug may help keep platelet levels safer so you can continue your cancer treatment.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.